Your browser doesn't support javascript.
loading
Hyperthyroidism Prevalence in China After Universal Salt Iodization.
Wang, Chuyuan; Li, Yongze; Teng, Di; Shi, Xiaoguang; Ba, Jianming; Chen, Bing; Du, Jianling; He, Lanjie; Lai, Xiaoyang; Li, Yanbo; Chi, Haiyi; Liao, Eryuan; Liu, Chao; Liu, Libin; Qin, Guijun; Qin, Yingfen; Quan, Huibiao; Shi, Bingyin; Sun, Hui; Tang, Xulei; Tong, Nanwei; Wang, Guixia; Zhang, Jin-An; Wang, Youmin; Xue, Yuanming; Yan, Li; Yang, Jing; Yang, Lihui; Yao, Yongli; Ye, Zhen; Zhang, Qiao; Zhang, Lihui; Zhu, Jun; Zhu, Mei; Shan, Zhongyan; Teng, Weiping.
Afiliação
  • Wang C; Department of Endocrinology and Metabolism, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Li Y; Department of Endocrinology and Metabolism, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Teng D; Department of Endocrinology and Metabolism, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Shi X; Department of Endocrinology and Metabolism, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Ba J; Department of Endocrinology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
  • Chen B; Department of Endocrinology, Southwest Hospital, Third Military Medical University, Chongqing, China.
  • Du J; Department of Endocrinology, First Affiliated Hospital, Dalian Medical University, Dalian, China.
  • He L; Department of Endocrinology, Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University, Jinfeng, China.
  • Lai X; Department of Endocrinology and Metabolism, Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Li Y; Department of Endocrinology, First Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Chi H; Department of Endocrinology, Hohhot First Hospital, Hohhot, China.
  • Liao E; Department of Endocrinology and Metabolism, Second Xiangya Hospital, Central South University, Changsha, China.
  • Liu C; Research Center of Endocrine and Metabolic Diseases, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • Liu L; Fujian Institute of Hematology, Union Hospital, Fujian Medical University, Fuzhou, China.
  • Qin G; International Medical Center, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
  • Qin Y; Department of Endocrinology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Quan H; Department of Endocrinology, Hainan General Hospital, Haikou, China.
  • Shi B; Department of Endocrinology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Sun H; Department of Endocrinology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Tang X; Department of Endocrinology, First Hospital of Lanzhou University, Lanzhou, China.
  • Tong N; State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
  • Wang G; Department of Endocrinology and Metabolism, First Affiliated Hospital of Jilin University, Changchun, China.
  • Zhang JA; Department of Endocrinology, Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, China.
  • Wang Y; Department of Endocrinology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Xue Y; Department of Endocrinology, The First People's Hospital of Yunnan Province, Kunming, China.
  • Yan L; Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Yang J; Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, China.
  • Yang L; Department of Endocrinology and Metabolism, People's Hospital of Tibet Autonomous Region, Lhasa, China.
  • Yao Y; Department of Endocrinology, Qinghai Provincial People's Hospital, Xining, China.
  • Ye Z; Zhejiang Center for Disease Control and Prevention (Zhejiang CDC), Hangzhou, China.
  • Zhang Q; Department of Endocrinology and Metabolism, Affiliated Hospital of Guiyang Medical University, Guiyang, China.
  • Zhang L; Department of Endocrinology, Second Hospital of Hebei Medical University, Shijiazhuang, China.
  • Zhu J; Department of Endocrinology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • Zhu M; Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
  • Shan Z; Department of Endocrinology and Metabolism, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Teng W; Department of Endocrinology and Metabolism, The First Affiliated Hospital of China Medical University, Shenyang, China.
Front Endocrinol (Lausanne) ; 12: 651534, 2021.
Article em En | MEDLINE | ID: mdl-34122333
Background: Universal salt iodization (USI) was implemented in mainland China in 1996. The prevalence of hyperthyroidism and its risk factors now require examination. Methods: Data were acquired from a nationwide Thyroid, Iodine, and Diabetes Epidemiological survey (TIDE 2015-2017) of 78,470 subjects from 31 provinces. Iodine status, and thyroid hormones and antibodies were measured. Results: After two decades of USI, the prevalence of overt hyperthyroidism (OH), Graves' disease (GD), severe subclinical hyperthyroidism (severe SCH), and mild subclinical hyperthyroidism (mild SCH) in mainland China was 0.78%, 0.53%, 0.22%, and 0.22%, respectively. OH and GD prevalence were higher in women than in men (OH: 1.16% vs. 0.64%, P<0.001; GD: 0.65% vs. 0.37%, P<0.001).Prevalence was significantly decreased after 60 years-of-age compared with 30-39 years-of-age (OH:0.61% vs. 0.81%, P<0.001; GD: 0.38% vs. 0.57%, P<0.001).Excessive iodine(EI) and deficient iodine(DI) were both related to increased prevalence of OH (odds ratio [OR] 2.09, 95% confidence interval [CI] 1.68-2.59; OR1.35, 95%CI 1.07-1.72, respectively); however, only deficient iodine was associated with increased prevalence of GD (OR1.67, 95%CI 1.30-2.15). Increased thyroid peroxidase antibody and thyroglobulin antibody levels were significantly associated with prevalence of OH and GD, but not severe SCH and mild SCH. Although hyperthyroidism was more prevalent in women, the association disappeared after adjusting for other factors such as antibody levels. Conclusion: OH and GD prevalences in mainland China are stable after two decades of USI. Iodine deficiency, elevated thyroid antibody levels, and middle age are the main risk factors for OH and GD. The severe SCH population, rather than the mild SCH population, shows similar characteristics to the OH population.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Graves / Cloreto de Sódio na Dieta / Hipertireoidismo / Iodo Tipo de estudo: Etiology_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Graves / Cloreto de Sódio na Dieta / Hipertireoidismo / Iodo Tipo de estudo: Etiology_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2021 Tipo de documento: Article